Merck KGaA’s pipeline has been dented by the ‘disappointing’ late-stage failure of Stimuvax in a programme with non-small cell lung cancer (NSCLC) patients. The Phase III START(a) tr…
SEATTLE, WA, Dec. 19, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that the pivotal Phase 3 clinical trial of L-BLP25 (formerly referred to as Stimuvax) known as START did not m…
FRANKFURT (Reuters) - An experimental lung cancer vaccine from Germany's Merck KGaA failed to improve survival in a pivotal study, dealing a blow to the company and the high-risk field of using vaccin…
